Would you like to participate ask a question join the surfers in our next episode?

S3-E25.5 – Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities

Surfing the NASH Tsunami shares Dr. Mazen Noureddin's portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.

This conversation is centered on Mazen Noureddin’s portion of Madrigal’s disease-focused presentation at the Chronic Liver Disease Foundation’s LiverConnect meeting this past March in Scottsdale, AZ. Mazen addresses issues of NAFLD Pathophysiology and NASH epidemiology, after which he answers questions and reviews key elements of the presentation with Roger Green.

This episode and all its conversations are sponsored by Madrigal Pharmaceuticals. Conversations 25.5 and 25.6 are a two-part summary of Madrigal’s disease-focused presentation at the recent CLDF LiverConnect meeting.

Request Transcript of This Episode
Request Transcript

NASH & Diabetes Podcast and NASH Tsunami Podcast